Growth factors of the EGF family and their receptors;Les facteurs de croissance de la famille de l'EGF et leurs récepteurs

Bulletin du Cancer

Volumn 94, Issue SUPPL. 7, 2007, Pages

  Hubert, Pierre ^a  

^a CNRS   (France)

Author keywords

EGF receptor; Epidermal growth factor (EGF); Erb B; Tyrosine kinase

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CETUXIMAB; CYTOPLASM PROTEIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR; IMATINIB; LAPATINIB; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PELITINIB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VECTIBIX;

CANCER THERAPY; CELL ONCOGENE; CELL PROLIFERATION; CELL TYPE; COLON CANCER; DIMERIZATION; DRUG EFFECT; DRUG TARGETING; HUMAN; OVARY CANCER; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; EPIDERMAL GROWTH FACTOR; GENES, ERBB-1; GENES, ERBB-2; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 36248992406     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0446     Document Type: Review

References (27)

1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases : targets for cancer therapy. Nat Rev Cancer 2004 ; 4 : 361-70.
2. Holbro T, Civenni G, Hynes N. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003 ; 284 : 99-110.
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000 ; 103 : 211-25.
4. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001 ; 411 : 355-65.
5. Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 2004 ; 50 : 23-38.
6. Holbro T, Hynes N. ErbB receptors : directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004 ; 44 : 195-217.
7. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001 ; 2 : 127-37.
8. Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006 ; 439 : 168-74.
9. Favre G. La voie des mitogen actived protein kinases (MAPK), cible de stratégies antitumorales. Bull Cancer 2006 ; 93(suppl) : 25-30.
10. Dreyer C, Faivre S, Raymond E. Voies de signalisation de la PI3K et de mTOR : perspectives de l'utilisation de la rapamycine et de ses dérivés en thérapie antitumorale ciblée. Bull Cancer 2006 ; 93(suppl) : 31-40.
11. Peschard P, Park M. Escape from Cbl-mediated downregulation : a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 2003 ; 3 : 519-23.
12. Casalini P, Iorio M, Galmozzi E, Ménard S. Role of HER receptors family in development and differentiation. J Cell Physiol 2004 ; 200 : 343-50.
13. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003 ; 12 : 541-52.
14. Ferguson KM. Active and inactive conformations of the epidermal growth factor receptor. Biochem Soc Trans 2004 ; 32 : 742-5.
15. Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000 ; 69 : 373-98.
16. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006 ; 125 : 1137-49.
17. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006 ; 6 : 714-27.
18. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004 ; 5 : 317-28.
19. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988 ; 242 : 933-5.
20. Scapin G. Structural biology in drug design : selective protein kinase inhibitors. Drug Discov Today 2002 ; 7 : 601-11.
21. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors : insights into drug design from structure. Science 2004 ; 303 : 1800-5.
22. Cohen P. Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002 ; 1 : 309-15.
23. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004 ; 3 : 1001-10.
24. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors - the bull's-eye hits the arrow. Cancer Cell 2004 ; 5 : 411-5.
25. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006 ; 12 : 7232-41.
26. Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR : the Achilles 'heal' of lung cancers? Trends Mol Med 2004 ; 10 : 481-6.
27. Keese M, Magdeburg RJ, Herzog T, Hasenberg T, Offterdinger M, Pepperkok R, et al. Imaging epidermal growth factor receptor phosphorylation in human colorectal cancer cells and human tissues. J Biol Chem 2005 ; 280 : 27826-31.